Şunu aradınız:: melanocytes (İngilizce - Maltaca)

the long term effects on the melanocytes and any consequences thereof are currently unknown.
l-effetti fit-tul fuq il-melanoċiti u il-konsegwenzi ta’ dan s’issa għadhom mhux magħrufa.

the long-term effects on the melanocytes and any consequences thereof are currently unknown.
l-effetti ta’ lżmien twil fuq il-melanoċiti u l-konsegwenzi ta’ dan s’issa għadhom mhumiex magħrufa.

the pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes.
il- bidla fil-pigmentazzjoni hi minħabba żieda fil-kontenut tal-melanin fil-melanoċiti u mhux minħabba żieda fin-numru ta’ melanoċiti.

the increased iris pigmentation appears to be caused by increased stimulation of melanin production in melanocytes and not by an increase in melanocyte number.
iż-żjieda fil-pigmentazzjoni tal-ħabba ta’ l-għajn jidher li hi kkaġunata minn żjieda fl-istimulazzjoni tal-produzzjoni ta’ melanin fil-melanoċiti u mhux minn żjieda fin-numru ta’-melanoċiti.

travatan may gradually change the eye colour by increasing the number of melanosomes (pigment granules) in melanocytes.
travatan b’mod gradwali jista’ jbiddel il-kulur tal-għajn billi jżid in-numru ta’ melanosomi (grani tal-pigment) fil-melanoċiti.

yervoy is used to treat adults with advanced melanoma (a type of skin cancer affecting cells called melanocytes).
yervoy jintuża fil-kura tal-adulti b’melanoma avvanzata (tip ta’ kanċer tal-ġilda li jaffettwa ċ-ċelloli msejħa melanoċiti).

3 ocular effects travoprost may gradually change the eye colour by increasing the number of melanosomes (pigment granules) in melanocytes.
3 effetti fl- għajnejn travoprost b’ mod gradwali jista ’ jbiddel il- kulur tal- għajn billi jżid in- numru ta ’ melanożomi (granijiet tal- pigment) fil- melanoċiti.

dinutuximab reacts specifically with the ganglioside gd2, which is highly expressed on the surface of neuroblastoma cells and minimally expressed on the surface of normal human neurons, peripheral pain fibres, and skin melanocytes.
dinutuximab jirreaġixxi speċifikament mal-ganglioside gd2, li hi espressa b’mod qawwi fuq il-wiċċ ta’ ċelluli ta’ newroblastoma u minimament espressa fuq il-wiċċ ta’ newroni umani normali, fibri periferali tal-uġigħ, u melanoċiti tal-ġilda.

carcinoid tumour (a tumour of the endocrine system that produces hormones); malignant melanoma (a type of skin cancer affecting cells called melanocytes).
tumur karċinojdu (tumur tas-sistema endokrinali li tipproduċi l-ormoni); melanoma malinja (tip ta’ kanċer tal-ġilda li jaffettwa ċ-ċelloli msejħa melanocytes).

introna is used as an add-on to anticancer treatments, • carcinoid tumour (a tumour of the endocrine system that produces hormones), • malignant melanoma (a type of skin cancer affecting cells called melanocytes).
introna hija użata bħala addizzjoni mat - trattamenti kontra l- kanċer. • tumur karċinojdu (tumur tas- sistema endokrinali li tipproduċi l- ormoni), • melanoma malinja (tip ta ’ kanċer tal- ġilda li jaffettwa ċ- ċelloli msejħa melanocytes).